Stock movement looks familiar.
Will the pattern hold?
Also, Botox rival, Revance Therapeutics, got approved. Longer lasting than Botox. Remains to be seen if it can eat into ABBV's market share.
Also, Botox rival, Revance Therapeutics, got approved. Longer lasting than Botox. Remains to be seen if it can eat into ABBV's market share.
免责声明
这些信息和出版物并不意味着也不构成TradingView提供或认可的金融、投资、交易或其它类型的建议或背书。请在使用条款阅读更多信息。